Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

医学 易普利姆玛 无容量 内科学 胰腺癌 肿瘤科 无进展生存期 养生 化疗 癌症 维持疗法 临床研究阶段 封锁 外科 胃肠病学 免疫疗法 受体
作者
Kim A. Reiss,Rosemarie Mick,Ursina Teitelbaum,Mark H. O’Hara,Charles Schneider,Ryan Massa,Thomas B. Karasic,Rashmi Tondon,Chioma Onyiah,Mary Kate Gosselin,Alyssa Donze,Susan M. Domchek,Robert H. Vonderheide
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (8): 1009-1020 被引量:84
标识
DOI:10.1016/s1470-2045(22)00369-2
摘要

Background Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade could offer synergistic tumour control. The aim of this study was to test the safety and antitumour activity of maintenance with PARP inhibition combined with immune checkpoint blockade in patients with advanced pancreatic cancer who had a stable response to platinum-based chemotherapy. Methods We conducted an open-label, randomised, phase 1b/2 study of niraparib plus anti-PD-1 (nivolumab) or anti-CTLA-4 (ipilimumab) therapy for patients with advanced pancreatic cancer whose cancer had not progressed after at least 16 weeks of platinum-based therapy. Patients were randomly assigned (1:1) via permuted block randomisation (block sizes 2 and 4) to niraparib 200 mg orally per day plus either nivolumab 240 mg intravenously every 2 weeks (later changed to 480 mg intravenously every 4 weeks based on manufacturer update) or ipilimumab 3 mg/kg intravenously every 3 weeks for four doses. The primary endpoints were safety and progression-free survival at 6 months. Treatment groups were not compared for activity, which was assessed in each group against a clinically meaningful progression-free survival at 6 months of 44% (null hypothesis). Superiority of a treatment regimen could be declared if 6-month progression-free survival was 60%, and inferiority if 6-month progression-free survival was 27%. All patients who received at least one dose of study treatment and had at least one post-treatment assessment of response according to Response Evaluation Criteria in Solid Tumours version 1.1 were included in the efficacy population. The safety population consisted of all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03404960, and enrolment is completed and follow-up is ongoing. Findings 91 patients were enrolled between Feb 7, 2018, and Oct 5, 2021 and were randomly assigned to niraparib plus nivolumab (n=46) or niraparib plus ipilimumab (n=45). Of these patients, 84 were evaluable for the progression-free survival endpoint (niraparib plus nivolumab=44; niraparib plus ipilimumab=40). Median follow-up was 23·0 months (IQR 15·0–31·5). 6-month progression-free survival was 20·6% (95% CI 8·3–32·9; p=0·0002 vs the null hypothesis of 44%) in the niraparib plus nivolumab group; and 59·6% (44·3–74·9; p=0·045) in the niraparib plus ipilimumab group. Ten (22%) of 46 patients in the niraparib plus nivolumab group and 23 (50%) of 45 patients in the niraparib plus ipilimumab group had a grade 3 or worse treatment-related adverse event. The most common grade 3 or worse adverse events in the niraparib plus nivolumab group were hypertension (in four [8%] patients), anaemia (two [4%]), and thrombocytopenia (two [4%]) whereas in the niraparib plus ipilimumab group these were fatigue (in six [14%]), anaemia (five [11%]), and hypertension (four [9%]). There were no treatment-related deaths. Interpretation The primary endpoint of 6-month progression-free survival was met in the niraparib plus ipilimumab maintenance group, whereas niraparib plus nivolumab yielded inferior progression-free survival. These findings highlight the potential for non-cytotoxic maintenance therapies in patients with advanced pancreatic cancer. Funding Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kk子发布了新的文献求助10
刚刚
刚刚
Lucas应助SSE采纳,获得10
1秒前
范范发布了新的文献求助10
2秒前
2秒前
我爱吃菜完成签到,获得积分10
3秒前
3秒前
赎罪完成签到 ,获得积分10
4秒前
Qsss完成签到,获得积分10
5秒前
ya发布了新的文献求助10
5秒前
5秒前
练得身形似鹤形完成签到 ,获得积分10
6秒前
6秒前
6秒前
7秒前
鹿港猫妖完成签到,获得积分20
8秒前
chen完成签到,获得积分10
8秒前
9秒前
阿湫发布了新的文献求助10
9秒前
9秒前
10秒前
崔悦欣发布了新的文献求助10
10秒前
希望天下0贩的0应助kk子采纳,获得10
11秒前
丰富的不惜完成签到,获得积分10
13秒前
票子发布了新的文献求助10
13秒前
华仔应助魏莱采纳,获得10
13秒前
F123发布了新的文献求助10
14秒前
shen发布了新的文献求助10
15秒前
15秒前
苗觉觉完成签到,获得积分10
16秒前
帕金森完成签到,获得积分10
17秒前
活力的妙芙完成签到,获得积分10
17秒前
赘婿应助疯子魔煞采纳,获得10
18秒前
橙橙橙完成签到,获得积分10
18秒前
18秒前
你好CDY完成签到,获得积分10
19秒前
19秒前
19秒前
万能图书馆应助希尔伯特采纳,获得10
19秒前
我是老大应助123采纳,获得10
20秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048